MAOI IN USE

Four MAOIs are currently available for treatment of depression: phenelzine tranylcypromine isocarboxazid and the agent that was prior-approved for Parkinson disease, but is now also approved for depression, selegiline, which is the first antidepressant available in a transdermal delivery system. Use of MAOIs is now limited due to the complicated dietary restrictions required of patients taking them